Genzyme's Clolar fails to gain support of FDA panel

09/2/2009 | Reuters

Genzyme did not get support from an FDA advisory panel to market pediatric leukemia drug Clolar to adults with acute myeloid leukemia. In a 9-3 vote, the panel advised the company to conduct a randomized trial of Clolar to provide "an evidence-based justification" that the product is more effective than other treatments.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT